GSK acquires rights to prostate-cancer candidate from Syndivia for up to £268 million
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Expanding US operations to address the increased demand for API development and manufacturing
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
Subscribe To Our Newsletter & Stay Updated